No difference in pubertal growth and final height between treated hypogonadal and non-hypogonadal thalassemic patients

Hormone Research

Volumn 62, Issue 1, 2004, Pages 17-22

  Caruso Nicoletti, Manuela ^a   De Sanctis, Vincenzo ^b   Raiola, Giuseppe ^c   Skordis, Nicos ^d   Mancuso, Michele ^a   Coco, Marilena ^a   Wonke, Beatrix ^e  

^a UNIVERSITY OF CATANIA   (Italy)

^b Azienda Ospedaliera Arcisp Sant'A   (Italy)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

^d Archbishop Makarios III Hospital   (Cyprus)

^e WHITTINGTON HOSPITAL   (United Kingdom)

Author keywords

thalassemia; Growth, pubertal; Hypogonadism; Puberty; Short stature

Indexed keywords

ETHINYLESTRADIOL; TESTOSTERONE;

ARTICLE; BETA THALASSEMIA; BODY HEIGHT; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; DELAYED PUBERTY; EVALUATION; FEMALE; GROWTH CURVE; GROWTH DISORDER; GROWTH INHIBITION; GROWTH RATE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE;

ADOLESCENT; BODY HEIGHT; ETHINYL ESTRADIOL; FEMALE; GROWTH; HUMANS; HYPOGONADISM; MALE; PUBERTY; SEX CHARACTERISTICS; TESTOSTERONE; THALASSEMIA;

EID: 3142752728     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077703     Document Type: Article

References (25)

1. Caruso-Nicoletti M, De Sanctis V, Capra M, et al: Short stature and body proportion in thalassemia. J Pediatr Endocrinol Metab 1998; 11(suppl 3):811-816.
2. Kattamis C, Liakopoulou T, Kattamis A: Growth and development in children with thalassemia major. Acta Paediatr Scand Suppl 1990;366:111-117.
3. De Sanctis V, Urso L: L'accrescimento staturale nella talassemia. Minerva Pediatr 1997;49:121-128.
4. De Sanctis V, Atti G, Banin P, et al: Growth in thalassemia major. Acta Med Auxol 1991;23:29-36.
5. De Sanctis V, Katz M, Vullo C, Bagni B, Ughi M, Wonke B: Effect of different treatment regimens on linear growth and final height in β-thalassemia major. Clin Endocrinol 1994;40:791-798.
6. Rodda CP, Reid ED, Johnson S, Doery J, Matthews R, Bowden DK: Short stature in homozygous beta-thalassemia is due to disproportionate truncal shortening. Clin Endocrinol 1995;42:587-592.
7. Kletzky OA, Costin G, Marrs RP, Bernstein G, March CM, Mishell DR Jr: Gonadotropin insufficiency in patients with thalassemia major. J Clin Endocrinol Metab 1979;48:901-905.
8. Wang C, Tso SC, Todd D: Hypogonadotropic hypogonadism in severe beta-thalassemia: Effect of chelation and pulsatile gonadotropin-releasing hormone therapy. J Clin Endocrinol Metab 1989;68:511-516.
9. De Sanctis V, on behalf of the Italian Working Group on Endocrine Complications in Non-Endocrine Diseases: Multicentre study on prevalence of endocrine complications in thalassemia major. Clin Endocrinol 1995;42:581-586.
10. Tanner JM, Whitehouse RH, Marshall WA, Healy MJR, Goldstein H: Assessment of Skeletal Maturity and Prediction of Adult Height (TW2 method). London, Academic Press, 1975.
11. Tanner JM, Whitehouse RH: Clinical and longitudinal standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976;51:170-179.
12. Buckler JMH, Wild J: Longitudinal study of height and weight at adolescence. Arch Dis Child 1987;62:1224-1232.
13. Buckler JMH: A Longitudinal Study of Adolescent Growth. London, Springer, 1990.
14. Borgna-Pignatti C, De Stefano P, Zonta L, et al: Growth and sexual maturation in thalassemia major. J Pediatr 1985;106:150-155.
15. Roth C, Pekrun A, Bartz M, et al: Short stature and failure of pubertal development in thalassemia major: Evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997;156:777-783.
16. Karlberg J, Kwan C, Gelander L, Albertsson-Wikland K: Pubertal growth assessment. Horm Res 2003;60:27-35.
17. Filosa A, Di Maio S, Baron I, Esposito G, Galati MG: Final height and body disproportion in thalassemic boys and girls with spontaneous or induced puberty. Acta Paediatr 2000;89:1295-1301.
18. Lederman HM, Choen A, Lee JW, Freedman MH, Gelfrand EW: Desferrioxamine: A reversible S-phase inhibitor of human lymphocyte proliferation. Blood 1968;64:748-753.
19. Llados i Vallory EA, Girot R, Lenoir G, et al: Studies of variation of subcutaneously infused desferrioxamine and iron movements in thalassemia children. Eur J Pediatr 1989;148:503-506.
20. Brill PW, Winchester P, Giardina PI, Cunningham-Rundles S: Deferoxamine-induced bone dysplasia in patients with thalassemia major. AJR Am J Roentgenol 1991;156:561-565.
21. De Virgiliis S, Congia M, Frau F, et al: Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988;113:661-669.
22. Olivieri NF, Koren G, Harris J, et al: Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992;14:48-56.
23. De Sanctis V, Pinamonti A, Di Palma A, et al: Growth and development in thalassemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155:368-372.
24. De Sanctis V, Stea S, Savarino L, et al: Growth hormone secretion and bone histomorphometric study in thalassemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Pediatr Endocrinol Metab 1998;11:827-833.
25. Caruso-Nicoletti M, De Sanctis V, Cavallo L, et al: Management of puberty for optimal auxological results in β-thalassemia. J Pediatr Endocrinol Metab 2001;14:939-944.